8 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorderRecruitingPhase 2 / Phase 32026-09-30NCT06635148
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyGeographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorderRecruitingPhase 32026-09-18NCT06541704
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56wet macular degenerationActive, not recruitingPhase 32026-09-03NCT06668064
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular DegenerationGeographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorderRecruitingNot applicable2026-08-26NCT06662162
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationGeographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorderActive, not recruitingPhase 1 / Phase 22026-08-17NCT06087458
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyDiabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorderEnrolling by invitationPhase 22026-08-05NCT05296447
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDNeovascular Age-Related Macular Degeneration (nAMD)Enrolling by invitationPhase 22026-08-05NCT05210803
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioGeographic Atrophy Secondary to Age-related Macular DegenerationRecruitingPhase 22026-06-24NCT07215390